Company news

AstraZeneca PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Acquisition of Fusion completed

June 5, 2024

Tagrisso plus chemo recommended for approval in EU

June 3, 2024

Dato-DXd improved OS in nonsquamous lung cancer

May 28, 2024

AstraZeneca to deliver $80bn revenue by 2030

May 21, 2024

AstraZeneca to manufacture ADCs in Singapore

May 20, 2024

SUPERNOVA Trial Met COVID-19 prevention endpoint

May 16, 2024

AstraZeneca completes Cellectis equity investment

May 7, 2024

Calquence combination improved PFS in 1L MCL

May 2, 2024

Truqap recommended for EU breast cancer approval

April 29, 2024

Enhertu improved PFS in HER2-low and ultralow

April 29, 2024

AstraZeneca increases 2024 dividend by 7%

April 11, 2024

Enhertu approved in US for HER2+ solid tumours

April 8, 2024

Imfinzi improved OS & PFS in limited-stage SCLC

April 5, 2024

Voydeya approved in US

April 2, 2024

FDA accepts Dato-DXd BLA for breast cancer

April 2, 2024

Ultomiris approved in the US for NMOSD

March 25, 2024

AstraZeneca to acquire Fusion

March 19, 2024

AstraZeneca to acquire Amolyt

March 14, 2024

EMA validates Dato-DXd MAAs for NSQ NSCLC and BC

March 4, 2024

Voydeya recommended for EU approval

February 26, 2024

Acquisition of Gracell completed

February 22, 2024

AstraZeneca prices a $5bn bond offering

February 22, 2024

AstraZeneca completes acquisition of Icosavax

February 19, 2024

Tagrisso plus chemo approved in US for lung cancer

February 19, 2024

FDA accepts Dato-DXd BLA for nonsquamous NSCLC

February 19, 2024

Tagrisso improved PFS in Stage III lung cancer

February 19, 2024

AstraZeneca acquires Gracell

December 27, 2023

Wainua (eplontersen) granted first US FDA approval

December 22, 2023

AstraZeneca to acquire Icosavax

December 12, 2023

Discontinuation of two CRYSTALIZE evidence trials

December 1, 2023

Truqap approved in US for HR+ breast cancer

November 17, 2023

Update on PACIFIC-2 Phase III trial for Imfinzi

November 14, 2023

Imfinzi combination improves PFS in liver cancer

November 9, 2023

Agreement with Eccogene for clinical stage GLP-1RA

November 9, 2023

9M and Q3 2023 results

November 9, 2023

AstraZeneca cell & gene therapy deal w/ Cellectis

November 1, 2023

AstraZeneca settles Nexium liability litigations

October 3, 2023

Dato-DXd improved PFS in breast cancer

September 22, 2023

Alexion completes Pfizer gene therapy agreement

September 20, 2023

Enhertu recommended in EU for HER2-mutant NSCLC

September 15, 2023

Fasenra Phase III EGPA trial met primary endpoint

September 11, 2023

Update on US review of Ultomiris for NMOSD

September 6, 2023

Alexion enters gene therapy agreement with Pfizer

July 28, 2023

Beyfortus approved in US for infant RSV prevention

July 17, 2023

Dato-DXd significantly improved PFS in lung cancer

July 3, 2023

nirsevimab recommended for infant RSV protection

June 9, 2023

AstraZeneca agreement with Quell Therapeutics

June 9, 2023

Imfinzi improved pCR in gastric and GEJ cancers

June 2, 2023

Lynparza approved in US for BRCAm prostate cancer

June 1, 2023

Imfinzi + Lynparza prolonged PFS in endometrial ca

May 26, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 242 decks. Every deck is listed under its year.